当前位置: X-MOL 学术J. Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Wearable sensors can reliably quantify gait alterations associated with disability in people with progressive multiple sclerosis in a clinical setting.
Journal of Neurology ( IF 4.8 ) Pub Date : 2020-05-28 , DOI: 10.1007/s00415-020-09928-8
Lorenza Angelini 1 , William Hodgkinson 2 , Craig Smith 2 , Jessie Moorman Dodd 2 , Basil Sharrack 3 , Claudia Mazzà 1 , David Paling 4
Affiliation  

Gait disability in people with progressive multiple sclerosis (MS) is difficult to quantify using existing clinical tools. This study aims to identify reliable and objective gait-based biomarkers to monitor progressive multiple sclerosis (MS) in clinical settings. During routine clinical visits, 57 people with secondary progressive MS and 24 healthy controls walked for 6 minutes wearing three inertial motion sensors. Fifteen gait measures were computed from the sensor data and tested for between-session reliability, for differences between controls and people with moderate and severe MS disability, and for correlation with Expanded Disability Status Scale (EDSS) scores. The majority of gait measures showed good to excellent between-session reliability when assessed in a subgroup of 23 healthy controls and 25 people with MS. These measures showed that people with MS walked with significantly longer step and stride durations, reduced step and stride regularity, and experienced difficulties in controlling and maintaining a stable walk when compared to controls. These abnormalities significantly increased in people with a higher level of disability and correlated with their EDSS scores. Reliable and objective gait-based biomarkers using wearable sensors have been identified. These biomarkers may allow clinicians to quantify clinically relevant alterations in gait in people with progressive MS within the context of regular clinical visits.



中文翻译:

在临床环境中,可穿戴传感器可以可靠地量化与进行性多发性硬化症患者的残障相关的步态变化。

进行性多发性硬化症(MS)患者的步态障碍很难使用现有的临床工具进行量化。这项研究旨在确定可靠和客观的基于步态的生物标志物,以监测临床环境中进行性多发性硬化症(MS)。在常规的临床就诊中,有57名继发性进行性MS患者和24名健康对照者戴着三个惯性运动传感器行走了6分钟。从传感器数据中计算出15个步态测量值,并测试了会话间的可靠性,对照组与中度和重度MS残疾者之间的差异,以及与扩展残疾状况量表(EDSS)得分的相关性。在由23名健康对照组和25名MS患者组成的亚组中评估时,大多数步态测量显示出良好的至会话间可靠性。这些措施表明,与对照组相比,MS患者的步行步伐和步幅持续时间明显更长,步伐和步幅规律性降低,并且在控制和维持稳定的步行过程中遇到困难。这些异常在残障程度较高的人群中显着增加,并且与他们的EDSS评分相关。已经确定了使用可穿戴传感器的可靠且客观的基于步态的生物标记。这些生物标志物可以使临床医生在定期进行临床就诊的情况下,量化进行性MS患者步态的临床相关变化。这些异常在残障程度较高的人群中显着增加,并且与他们的EDSS评分相关。已经确定了使用可穿戴传感器的可靠且客观的基于步态的生物标记。这些生物标志物可以使临床医生在定期进行临床就诊的情况下,量化进行性MS患者步态的临床相关变化。这些异常在残障程度较高的人群中显着增加,并且与他们的EDSS评分相关。已经确定了使用可穿戴传感器的可靠且客观的基于步态的生物标记。这些生物标志物可以使临床医生在定期进行临床就诊的情况下,量化进行性MS患者步态的临床相关变化。

更新日期:2020-05-28
down
wechat
bug